Baricitinib Curative Repression of HIV-1

Inclusion Criteria: * Documented HIV infection * On continuous ART for at least 96 weeks before enrollment, with no interruption of ART for 7 consecutive days or longer in the 48 weeks before enrollment. * Plasma HIV-1 RNA levels of \<50 copies/mL for at least 96 weeks (a minimum of two measures), and \<50 copies/mL for a sample obtained within 90 days, before enrollment. * CD4+ T-cell count ≥500 cells/mm3 obtained within 90 days prior to enrollment * No known history of CD4+ T-cell count nadir \<200 cells/mm3 * Negative pregnancy test at time of study enrollment * Additional laboratory criteria may apply. Exclusion Criteria: * \< 18 years of age or \> 70 years of age * Pregnancy or breastfeeding, as determined by a blood pregnancy test * History of AIDS-defining illness, except for recurrent pneumonia. * History of progressive multifocal leukoencephalopathy or clinically significant HIV-associated neurocognitive disease. * Untreated latent tuberculosis infection (which will be screened for before entry). If there is a prior positive test, the test does not need to be repeated at screening. * History of use of any immunomodulatory medications within 6 months before enrollment, including systemic corticosteroids (\>14 days), immunosuppressants, anti-cancer, interleukins, systemic interferons, systemic chemotherapy, or other medications that the site investigator feels could have an immunomodulatory effect. * History of deep venous thrombosis * Cardiovascular disease (Corona…